Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs13281615
rs13281615
G 0.800 GeneticVariation GWASCAT Association analysis identifies 65 new breast cancer risk loci. 29059683

2017

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE Previous genome-wide association studies among women of European ancestry identified two independent breast cancer susceptibility loci represented by single nucleotide polymorphisms (SNPs) rs13281615 and rs11780156 at 8q24. 27087578

2016

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE This meta-analysis suggests that 8q24 rs13281615 polymorphism is a risk factor for susceptibility to BC in Asians, Caucasians and in overall population, While, there was no association in Africans. 27634905

2016

dbSNP: rs13281615
rs13281615
G 0.800 GeneticVariation GWASCAT Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. 25751625

2015

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE The results indicated that the rs13281615 G allele significantly increased BC risk, with an odds ratio (OR) of 1.23 (95% confidence interval (CI) = 1.03-1.46) under the allelic model. 24414391

2014

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE No significant association was observed for rs13281615 (8q24) with BC risk in women from the Chilean population. 24532140

2014

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE These results suggest that the GG genotype of SNP rs13281615 plays a role in breast cancer likely by influencing PVT1 expression, and that during oncogenesis, "protective" mutations could occur. 24780616

2014

dbSNP: rs13281615
rs13281615
G 0.800 GeneticVariation GWASCAT Large-scale genotyping identifies 41 new loci associated with breast cancer risk. 23535729

2013

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE In conclusion, this meta-analysis suggests that the 8q24 rs13281615A > G polymorphism is a low-penetrant risk factor for developing breast cancer but may not be in Africans. 23292077

2013

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE G-allele genotypes of rs13281615 at 8q24 polymorphism are a risk factor for developing BC, while the AA genotype is a protective factor. 23565189

2013

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE Our study indicated that SNP rs13281615 at 8q24 was associated with the consumption of epidural ropivacaine during breast cancer surgery in northeastern Chinese women. 23577780

2013

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE 2008, this is the second study to confirm the association of 8q24.21-rs13281615 with breast cancer outcomes. 23717390

2013

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE A dose-dependent association was observed between the risk of breast cancer and the genetic risk score, which was an aggregate measure of alleles in seven selected variants, namely FGFR2-rs2981579, TOX3/TNRC9-rs3803662, C6orf97-rs2046210, 8q24-rs13281615, SLC4A7-rs4973768, LSP1-rs38137198, and CASP8-rs10931936. 22160591

2012

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE Confirmed BC risk SNPs rs17468277 (CASP8), rs1982073 (TGFB1), rs2981582 (FGFR2), rs13281615 (8q24), rs3817198 (LSP1), rs889312 (MAP3K1), rs3803662 (TOX3), rs13387042 (2q35), rs4973768 (SLC4A7), rs6504950 (COX11) and rs10941679 (5p12) were genotyped for 25 853 BC patients with the available follow-up; 62 other SNPs, which have been suggested as BC risk SNPs by a GWAS or as candidate SNPs from individual studies, were genotyped for replication purposes in subsets of these patients. 22532573

2012

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE Only 5 out of 9 GWAS breast cancer loci were found to be significantly associated with breast cancer in Tunisians: The rs1219648 (G vs. A allele: OR = 1.36, P = 1 × 10(-3)) and rs2981582 (A vs. G allele: OR = 1.55, P = 3 × 10(-6)) of FGFR2 gene; the rs8051542 of the TNRC9 gene (T vs. C allele: OR = 1.40, P = 4 × 10(-4)); the rs889312 of the MAP3K1 gene (C vs. A allele: OR = 1.33, P = 3 × 10(-3)) and the rs13281615 located on 8q24 (G vs. A allele: OR = 1.21, P = 0.03). 22910930

2012

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE Consistent with their breast cancer associations, rs3817198 (LSP1) and rs13281615 (8q) were associated with dense area and percent dense area (all P(x) and P(c) <0.05), and rs889312 (MAP3K1), rs2107425 (H19), and rs17468277 (CASP8) were marginally associated with dense area (some P(x) or P(c) <0.05). 20145138

2010

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE Eight SNPs (rs2046210, rs1219648, rs3817198, rs8051542, rs3803662, rs889312, rs10941679, and rs13281615), each of which reflected a genetically independent locus, were found to be associated with the risk of breast cancer. 20484103

2010

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE Further studies are required to confirm whether the adjacent breast cancer-associated variant rs13281615 may be inversely associated with prostate cancer risk. 18625567

2009

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE The known breast cancer SNPs rs13281615, rs2981582 and rs3803662 were confirmed as associated with breast cancer risk (P (allelic test) = 1.8 x 10(-2), OR = 1.17; P (allelic test) = 2.2 x 10(-3), OR = 1.22; P (allelic test) = 5.1 x 10(-2), OR = 1.15, respectively) in the West of Ireland cohort. 19005751

2009

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE SNP rs13281615 at 8q24 was not associated with breast cancer for either BRCA1 or BRCA2 mutation carriers, but the estimated association for BRCA2 mutation carriers (per-allele HR = 1.06, 95% CI: 0.98-1.14) was consistent with odds ratio estimates derived from population-based case-control studies. 19656774

2009

dbSNP: rs13281615
rs13281615
0.800 GeneticVariation BEFREE Our analysis provides further evidence of the relationship between rs13281615 and risk of breast cancer, with heterozygote odds ratio (OR) 1.30 95% confidence interval (CI) 1.09-1.54 and homozygote OR 1.52 (95% CI, 1.22-1.89; P trend = 0.00003), and confirms the prediction that the risk is substantially higher in this genetically enriched series (OR per allele, 1.24; 95% CI, 1.12-1.38) than in a large series of mainly unselected cases (reported OR per allele, 1.08; 95% CI, 1.05-1.11). 18349290

2008

dbSNP: rs13281615
rs13281615
C 0.800 GeneticVariation GWASCAT Genome-wide association study identifies novel breast cancer susceptibility loci. 17529967

2007